Novo Nordisk A/S (NVO)
91.29
-3.44
(-3.63%)
USD |
NYSE |
Sep 21, 16:00
92.16
+0.87
(+0.95%)
Pre-Market: 08:40
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 408.38B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 85.17% |
| Valuation | |
| PE Ratio | 43.33 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 14.52 |
| Price to Book Value | 30.93 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.2209 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2841 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 25.29% |
Profile
| With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Nov. 02, 2023 |
| Last Earnings Release | Aug. 10, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 18, 2023 |
Ratings
Profile
| With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
| URL | https://www.novonordisk.com |
| Investor Relations URL | https://www.novonordisk.com/investors.html |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Nov. 02, 2023 |
| Last Earnings Release | Aug. 10, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 18, 2023 |